Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to 2025 American Association for Thoracic Surgery (AATS) Expert Consensus Document: Surgical management of acute myocardial infarction and associated complications: The Journal of Thoracic and Cardiovascular Surgery, Volume 170, Issue 5, 2025, Pages 1327-1344.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Long-term outcomes of postoperative atrial fibrillation after cardiac surgery: Results from 19,000 patients.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Conventional Cardiac Surgery in Donation After Circulatory Death Heart Transplantation: A United Network for Organ Sharing Registry Analysis.

Clinical transplantation·2026
Same author

Effects of Functional Warm Ischemia Time on Posttransplant Outcomes in Donation After Circulatory Death Heart Transplantation Using Direct Procurement and Perfusion.

Transplantation·2026
Same author

Impact of Circulatory Arrest Duration on Perioperative Mortality: Insights From More Than 1200 Aortic Arch Reconstructions.

The Annals of thoracic surgery·2026
Same author

Frozen Elephant Trunk for Retrograde Type A Aortic Dissection Within 1 Year Following Heart Transplant.

JACC. Case reports·2026

Related Experiment Video

Updated: Jul 16, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Targeting CD47: NO limit on therapeutic potential

David J Kaczorowski, Timothy R Billiar

    Circulation Research
    |March 17, 2007
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
    08:13

    Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

    Published on: December 3, 2020

    Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
    09:12

    Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

    Published on: June 14, 2024

    Related Experiment Videos

    Last Updated: Jul 16, 2026

    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
    08:46

    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

    Published on: November 12, 2019

    Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
    08:13

    Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

    Published on: December 3, 2020

    Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
    09:12

    Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

    Published on: June 14, 2024